Innovative use of topical metronidazole.
Metronidazole is a synthetic nitroimidazole derivative with antimicrobial and antiinflammatory properties. It was the first topical therapy approved solely for rosacea and remains a cornerstone of rosacea management. This article reviews the optimal use of topical metronidazole in the treatment of rosacea and other innovative but off-label dermatologic uses reported in the literature.
The Dermatology Centre, 124-42 Avenue South West, Calgary, Alberta T2S3B3, Canada. catherinezip@shaw.ca
Catherine M
CM
Zip
D056150:Acute Generalized Exanthematous Pustulosis / Q000188:drug therapy; D000279:Administration, Cutaneous; D000328:Adult; D000890:Anti-Infective Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D002648:Child; D019557:Dermatitis, Perioral / Q000188:drug therapy; D012628:Dermatitis, Seborrheic / Q000188:drug therapy; D004311:Double-Blind Method; D003875:Drug Eruptions / Q000175:diagnosis / Q000209:etiology; D066246:ErbB Receptors / Q000037:antagonists & inhibitors; D005260:Female; D006801:Humans; D008297:Male; D008795:Metronidazole / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D015337:Multicenter Studies as Topic; D056687:Off-Label Use; D016032:Randomized Controlled Trials as Topic; D012393:Rosacea / Q000188:drug therapy*; D035703:Therapies, Investigational; D014947:Wounds and Injuries / Q000188:drug therapy
D000890:Anti-Infective Agents; D000894:Anti-Inflammatory Agents, Non-Steroidal; D008795:Metronidazole; D066246:ErbB Receptors